Peptide interactions with G-protein coupled receptors.
暂无分享,去创建一个
[1] K. Palczewski,et al. Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.
[2] F. Richards,et al. Thermodynamics of protein-peptide interactions in the ribonuclease S system studied by titration calorimetry. , 1990, Biochemistry.
[3] M. Ermolaeva,et al. Receptor-G protein coupling is established by a potential conformational switch in the beta gamma complex. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[4] Determination of peptide contact points in the human angiotensin II type I receptor (AT1) with photosensitive analogs of angiotensin II. , 1999, Molecular endocrinology.
[5] Partho Ghosh,et al. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2 , 1996, Nature.
[6] A. Billich,et al. Analysis of subsite preferences of HIV-1 proteinase using MA/CA junction peptides substituted at the P3-P1' positions. , 1991, Archives of biochemistry and biophysics.
[7] R. Cone,et al. Compounds that activate the mouse melanocortin-1 receptor identified by screening a small molecule library based upon the beta-turn. , 1999, Journal of medicinal chemistry.
[8] V. Madison,et al. Peptide mimetics of thyrotropin-releasing hormone based on a cyclohexane framework: design, synthesis, and cognition-enhancing properties. , 1995, Journal of medicinal chemistry.
[9] M. Belfort,et al. Mechanisms of Intron Mobility (*) , 1995, The Journal of Biological Chemistry.
[10] C. Dooley,et al. New opioid peptides, peptidomimetics, and heterocyclic compounds from combinatorial libraries. , 1999, Biopolymers.
[11] S. Sprang,et al. Structure of RGS4 Bound to AlF4 −-Activated Giα1: Stabilization of the Transition State for GTP Hydrolysis , 1997, Cell.
[12] K. Ward,et al. Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic. , 2000, Journal of medicinal chemistry.
[13] D. Rhodes,et al. Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. , 1991, Journal of medicinal chemistry.
[14] J. García-Sancho,et al. Cytochrome P450 may regulate plasma membrane Ca2+ permeability according to the filling state of the intracellular Ca2+ stores , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[15] E G McMahon,et al. Conformational restriction of angiotensin II: cyclic analogues having high potency. , 1990, Journal of medicinal chemistry.
[16] A G Cochran,et al. Antagonists of protein-protein interactions. , 2000, Chemistry & biology.
[17] B. Imperiali,et al. Pyridoxamine-amino acid chimeras in semisynthetic aminotransferase mimics. , 1997, Protein engineering.
[18] A Wlodawer,et al. Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor. , 1991, Biochemistry.
[19] H. Khorana,et al. Mapping light-dependent structural changes in the cytoplasmic loop connecting helices C and D in rhodopsin: a site-directed spin labeling study. , 1995, Biochemistry.
[20] N. Gautam,et al. A farnesylated domain in the G protein gamma subunit is a specific determinant of receptor coupling. , 1994, The Journal of biological chemistry.
[21] M. Ghadiri,et al. Secondary structure nucleation in peptides. Transition metal ion stabilized .alpha.-helices , 1990 .
[22] M. Galas,et al. Synthesis and biological activities of pseudopeptide analogues of the C-terminal heptapeptide of cholecystokinin. On the importance of the peptide bonds. , 1987, Journal of medicinal chemistry.
[23] B H Arison,et al. Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[24] P. Schiller,et al. The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists. , 1999, Biopolymers.
[25] A. Patchett,et al. Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential. , 1998, Journal of medicinal chemistry.
[26] A T Brünger,et al. Three-dimensional structure of an angiotensin II-Fab complex at 3 A: hormone recognition by an anti-idiotypic antibody. , 1992, Science.
[27] V J Hruby,et al. Design of peptides, proteins, and peptidomimetics in chi space. , 1997, Biopolymers.
[28] K Wüthrich,et al. The NMR structure of cyclosporin A bound to cyclophilin in aqueous solution. , 1991, Biochemistry.
[29] S. Karnik,et al. The Docking of Arg2 of Angiotensin II with Asp281 of AT1 Receptor Is Essential for Full Agonism (*) , 1995, The Journal of Biological Chemistry.
[30] P. Garratt,et al. The design of non-peptide human bradykinin B2 receptor antagonists employing the benzodiazepine peptidomimetic scaffold. , 1999, Bioorganic & medicinal chemistry letters.
[31] J. Bali,et al. Synthesis of pseudo-peptide analogues of the C-terminal tetrapeptide of gastrin and evaluation of their biological activity on acid secretion. , 2009, International journal of peptide and protein research.
[32] Robyn L. Stanfield,et al. An αβ T Cell Receptor Structure at 2.5 Å and Its Orientation in the TCR-MHC Complex , 1996, Science.
[33] D. Norbeck,et al. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. , 1990, Science.
[34] J. Becker,et al. Synthesis, biological activity, and conformational analysis of peptidomimetic analogues of the Saccharomyces cerevisiae alpha-factor tridecapeptide. , 1998, Biochemistry.
[35] S. Schreiber,et al. Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3-ligand interactions. , 1995, Science.
[36] Max F. Perutz,et al. Hemoglobin as a receptor of drugs and peptides: x-ray studies of the stereochemistry of binding , 1986 .
[37] T. Burks,et al. Morphiceptin and β‐casomorphin‐5 analogues containing a reduced peptide bond: Selective μ‐receptor agonists and a novel μ antagonist, H‐Tyr‐Proψ(CH2‐NH)Phe‐Pro‐Gly‐OH , 1992 .
[38] G. Wider,et al. Structure of human cyclophilin and its binding site for cyclosporin A determined by X-ray crystallography and NMR spectroscopy , 1991, Nature.
[39] I. Wilson,et al. Structural evidence for induced fit as a mechanism for antibody-antigen recognition. , 1994, Science.
[40] T. Schwartz,et al. Metal‐Ion Sites as Structural and Functional Probes of Helix–Helix Interactions in 7TM Receptors , 1997, Annals of the New York Academy of Sciences.
[41] I. Kuntz,et al. Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[42] P. Gallant,et al. Detection of small-molecule enzyme inhibitors with peptides isolated from phage-displayed combinatorial peptide libraries. , 2000, Chemistry & biology.
[43] Klaus Hofmann,et al. S-peptide-S-protein system. Model for hormone-receptor interaction , 1973 .
[44] Paul A. Bartlett,et al. Metal Coordination as a Method for Templating Peptide Conformation , 1996 .
[45] Thyrotropin releasing hormone analogs: a building block approach to the construction of tetracyclic peptidomimetics. , 1998, Bioorganic & medicinal chemistry letters.
[46] A. Smolyar,et al. The crystal structure of a T cell receptor in complex with peptide and MHC class II. , 1999, Science.
[47] Berthold Von Freyberg,et al. Receptor-induced conformation change of the immunosuppressant cyclosporin A. , 1991, Science.
[48] V. Hruby,et al. beta-Methylation of the Phe7 and Trp9 melanotropin side chain pharmacophores affects ligand-receptor interactions and prolonged biological activity. , 1997, Journal of medicinal chemistry.
[49] J Engel,et al. Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. , 1994, The Journal of biological chemistry.
[50] L. Suva,et al. Parathyroid Hormone-Receptor Interactions Identified Directly by Photocross-linking and Molecular Modeling Studies* , 1998, The Journal of Biological Chemistry.
[51] B. Meyer,et al. Mapping the active site of angiotensin-converting enzyme by transferred NOE spectroscopy. , 2000, Journal of medicinal chemistry.
[52] Henry I. Mosberg. Complementarity of δ opioid ligand pharmacophore and receptor models , 1999 .
[53] J. Bali,et al. Synthesis and biological activities of some pseudo-peptide analogues of tetragastrin: the importance of the peptide backbone. , 1985, Journal of medicinal chemistry.
[54] Y. Shi,et al. Metallopeptide approach to the design of biologically active ligands: design of specific human neutrophil elastase inhibitors. , 1999, Bioorganic & medicinal chemistry letters.
[55] J. Bushweller,et al. Investigation of an octapeptide inhibitor of Escherichia coli ribonucleotide reductase by transferred nuclear Overhauser effect spectroscopy. , 1991, Biochemistry.
[56] B. E. Evans,et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of Medicinal Chemistry.
[57] A. Gronenborn,et al. Solution structure of a calmodulin-target peptide complex by multidimensional NMR. , 1994, Science.
[58] W. Hutton,et al. Emerimicins III and IV and Their Ethylalanine12 Epimers. Facilitated Chemical-Enzymatic Synthesis and a Qualitative Evaluation of Their Solution Structures , 1992 .
[59] N. Tarasova,et al. Inhibition of G-protein-coupled Receptor Function by Disruption of Transmembrane Domain Interactions* , 1999, The Journal of Biological Chemistry.
[60] Garland R. Marshall,et al. Pro-D-NMe-Amino Acid and D-Pro-NMe-Amino Acid: Simple, Efficient Reverse-Turn Constraints , 1995 .
[61] B. Stoddard,et al. Calcineurin-immunosuppressor complexes. , 1996, Current opinion in structural biology.
[62] A Aubry,et al. A crystal molecular conformation of leucine‐enkephalin related to the morphine molecule , 1989, Biopolymers.
[63] The structure of aridicin A. An integrated approach employing 2D NMR, energy minimization and distance constraints , 1986 .
[64] M. Katharine Holloway,et al. X-Ray Crystal Structure of the HIV Protease Complex with L-700,417, an Inhibitor with Pseudo C2 Symmetry , 1991 .
[65] D. Coy,et al. Effect of the CH2NH and CH2NAc peptide bond isosteres on the antagonistic and histamine releasing activities of a luteinizing hormone-releasing hormone analogue. , 1988, Journal of medicinal chemistry.
[66] Anna Tempczyk,et al. Crystal structures of human calcineurin and the human FKBP12–FK506–calcineurin complex , 1995, Nature.
[67] J. Becker,et al. Mutations affecting ligand specificity of the G-protein-coupled receptor for the Saccharomyces cerevisiae tridecapeptide pheromone. , 1998, Biochimica et biophysica acta.
[68] J. Louis,et al. Kinetic and modeling studies of S3-S3' subsites of HIV proteinases. , 1992, Biochemistry.
[69] J. Baldwin. The probable arrangement of the helices in G protein‐coupled receptors. , 1993, The EMBO journal.
[70] K. Nakanishi,et al. Movement of retinal along the visual transduction path. , 2000, Science.
[71] C. W. Roberts,et al. THE SYNTHESIS OF AN OCTAPEPTIDE AMIDE WITH THE HORMONAL ACTIVITY OF OXYTOCIN , 1953 .
[72] Dorica Mayer,et al. A unique geometry of the active site of angiotensin-converting enzyme consistent with structure-activity studies , 1987, J. Comput. Aided Mol. Des..
[73] D. Rich,et al. Peptidomimetics derived from natural products , 1993, Medicinal research reviews.
[74] Stephen W. Fesik,et al. Lithium chloride perturbation of cis-trans peptide bond equilibria: effect on conformational equilibria in cyclosporin A and on time-dependent inhibition of cyclophilin , 1992 .
[75] K Wüthrich,et al. TROSY in triple-resonance experiments: new perspectives for sequential NMR assignment of large proteins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[76] Tyrosine alone exhibits opiate-like activity when linked to an amphipathic hydrocarbon chain , 1988 .
[77] A. Tomasselli,et al. A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base. , 1991, The Journal of biological chemistry.
[78] A Wlodawer,et al. X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[79] R. Huber,et al. The structure of a complex of recombinant hirudin and human alpha-thrombin. , 1990, Science.
[80] K. Hofmann,et al. Signal transfer from rhodopsin to the G-protein: evidence for a two-site sequential fit mechanism. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[81] X Zhang,et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. , 1998, Biochemical and biophysical research communications.
[82] Maria Miller,et al. Crystal structure of a retroviral protease proves relationship to aspartic protease family , 1989, Nature.
[83] D. Underwood,et al. Structural Requirements for the Activation of the Human Growth Hormone Secretagogue Receptor by Peptide and Nonpeptide Secretagogues , 1997 .
[84] P. Hopkins,et al. Metal ion enhanced helicity in synthetic peptides containing unnatural, metal-ligating residues , 1990 .
[85] I. Mian,et al. Structure, function and properties of antibody binding sites. , 1991, Journal of molecular biology.
[86] K. Garcia,et al. Structural basis of T cell recognition. , 1999, Annual review of immunology.
[87] D. Coy,et al. Solid-phase synthesis and biological properties of psi [CH2NH] pseudopeptide analogues of a highly potent somatostatin octapeptide. , 1987, Journal of medicinal chemistry.
[88] W. Vale,et al. D-Trp8-somatostatin: an analog of somatostatin more potent than the native molecule. , 1975, Biochemical and biophysical research communications.
[89] D Altschuh,et al. A conformation of cyclosporin A in aqueous environment revealed by the X-ray structure of a cyclosporin-Fab complex. , 1992, Science.
[90] P E Wright,et al. Defining solution conformations of small linear peptides. , 1991, Annual review of biophysics and biophysical chemistry.
[91] G. Bitan,et al. Photoaffinity Cross-linking Identifies Differences in the Interactions of an Agonist and an Antagonist with the Parathyroid Hormone/Parathyroid Hormone-related Protein Receptor* , 2000, The Journal of Biological Chemistry.
[92] G R Marshall,et al. Ac-[3- and 4-alkylthioproline31]-CCK4 analogs: synthesis and implications for the CCK-B receptor-bound conformation. , 1995, Journal of medicinal chemistry.
[93] A. Doig,et al. Toward the semiquantitative estimation of binding constants guides for peptide peptide binding in aqueous solution , 1991 .
[94] H. Hamm,et al. The 2.0 Å crystal structure of a heterotrimeric G protein , 1996, Nature.
[95] I. Gantz,et al. Molecular Basis for the Interaction of [Nle4,d-Phe7]Melanocyte Stimulating Hormone with the Human Melanocortin-1 Receptor (Melanocyte α-MSH Receptor)* , 1997, The Journal of Biological Chemistry.
[96] S. O. Smith,et al. Magic angle spinning NMR of the protonated retinylidene Schiff base nitrogen in rhodopsin: expression of 15N-lysine- and 13C-glycine-labeled opsin in a stable cell line. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[97] Garland R. Marshall,et al. Three-dimensional structure of peptide—protein complexes: implications for recognition , 1992 .
[98] A Wlodawer,et al. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. , 1989, Science.
[99] D. Coy,et al. Analogues of growth hormone-releasing factor (1-29) amide containing the reduced peptide bond isostere in the N-terminal region. , 1990, Journal of medicinal chemistry.
[100] H. Khorana,et al. Structural features and light-dependent changes in the cytoplasmic interhelical E-F loop region of rhodopsin: a site-directed spin-labeling study. , 1996, Biochemistry.
[101] Garland R. Marshall,et al. 3D-QSAR of angiotensin-converting enzyme and thermolysin inhibitors: A comparison of CoMFA models based on deduced and experimentally determined active site geometries , 1993 .
[102] K. Aston,et al. Synthesis of conformationally tailored pentaazacyclopentadecanes. Preorganizing peptide cyclizations , 1997 .
[103] L. Suva,et al. Direct mapping of an agonist-binding domain within the parathyroid hormone/parathyroid hormone-related protein receptor by photoaffinity crosslinking. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[104] Stephen Hanessian,et al. Design and synthesis of conformationally constrained amino acids as versatile scaffolds and peptide mimetics , 1997 .
[105] C. Dobson,et al. Antigen mobility in the combining site of an anti-peptide antibody. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[106] Luis Reuss. Focus on "Effect of expressing the water channel aquaporin-1 on the CO2 permeability of Xenopus oocytes". , 1998, American journal of physiology. Cell physiology.
[107] G. Marshall,et al. Determination of a precise interatomic distance in a helical peptide by REDOR NMR , 1990 .
[108] E. R. Stimson,et al. Mapping Peptide-binding Domains of the Substance P (NK-1) Receptor from P388D Cells with Photolabile Agonists (*) , 1995, The Journal of Biological Chemistry.
[109] R. Hirschmann. Medicinal Chemistry in the Golden Age of Biology: Lessons from Steroid and Peptide Research , 1991 .
[110] J. Rothbard,et al. Interactions between Immunogenic Peptides and MHC Proteins , 1991 .
[111] G. Byk,et al. Comparison of the conformation of active and nonactive backbone cyclic analogs of substance P as a tool to elucidate features of the bioactive conformation: NMR and molecular dynamics in DMSO and water. , 1994, Journal of medicinal chemistry.
[112] D. Riley,et al. Manganese macrocyclic ligand complexes as mimics of superoxide dismutase , 1994 .
[113] D. Madden. The three-dimensional structure of peptide-MHC complexes. , 1995, Annual review of immunology.
[114] Shu-Kun Lin. Pharmacophore Perception, Development and Use in Drug Design. Edited by Osman F. Güner , 2000 .
[115] G. Marshall,et al. Novel cyclic analogs of angiotensin II with cyclization between positions 5 and 7: conformational and biological implications. , 1996, Journal of medicinal chemistry.
[116] R. Huber,et al. The structure of residues 7-16 of the A alpha-chain of human fibrinogen bound to bovine thrombin at 2.3-A resolution. , 1994, The Journal of biological chemistry.
[117] S. Karnik,et al. Interaction of Phe8 of Angiotensin II with Lys199 and His256 of AT1 Receptor in Agonist Activation (*) , 1995, The Journal of Biological Chemistry.
[118] G R Marshall,et al. Factors governing helical preference of peptides containing multiple alpha,alpha-dialkyl amino acids. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[119] H. Hamm,et al. Potent Peptide Analogues of a G Protein Receptor-binding Region Obtained with a Combinatorial Library (*) , 1996, The Journal of Biological Chemistry.
[120] J. Bali,et al. Phenylethylamide derivatives of the C-terminal tetrapeptide of gastrin. Potent inhibitors of gastrin-stimulated acid secretion. , 2009, International journal of peptide and protein research.
[121] J. Alderfer,et al. Three-dimensional structure of the cytoplasmic face of the G protein receptor rhodopsin. , 1997, Biochemistry.
[122] G R Marshall,et al. Light-activated rhodopsin induces structural binding motif in G protein alpha subunit. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[123] W. Greenlee,et al. Dual agonistic and antagonistic property of nonpeptide angiotensin AT1 ligands: susceptibility to receptor mutations. , 1997, Molecular pharmacology.
[124] H. Scheraga,et al. High-resolution NMR studies of fibrinogen-like peptides in solution: structure of a thrombin-bound peptide corresponding to residues 7-16 of the A alpha chain of human fibrinogen. , 1989, Biochemistry.
[125] P. Caron,et al. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex , 1995, Cell.
[126] A. Milon,et al. Transferred nuclear Overhauser effect analyses of membrane-bound enkephalin analogues by 1H nuclear magnetic resonance: correlation between activities and membrane-bound conformations. , 1990, Biochemistry.
[127] J. Springer,et al. Structure and function of retroviral proteases. , 1991, Annual review of biophysics and biophysical chemistry.
[128] G R Marshall,et al. Conformationally restricted TRH analogs: a probe for the pyroglutamate region. , 1996, Journal of medicinal chemistry.
[129] N. Gautam,et al. Efficient Interaction with a Receptor Requires a Specific Type of Prenyl Group on the G Protein γ Subunit (*) , 1995, The Journal of Biological Chemistry.
[130] Garland R. Marshall,et al. Electrochemical Cyclization of Dipeptides toward Novel Bicyclic, Reverse-Turn Peptidomimetics. 1. Synthesis and Conformational Analysis of 7,5-Bicyclic Systems , 1995 .
[131] V. Chhajlani,et al. Identification of ligand binding residues in extracellular loops of the melanocortin 1 receptor. , 1996, Biochemical and biophysical research communications.
[132] G. Turcatti,et al. Characterization of Non-peptide Antagonist and Peptide Agonist Binding Sites of the NK1 Receptor with Fluorescent Ligands* , 1997, The Journal of Biological Chemistry.
[133] Arthur A. Patchett,et al. Chapter 26. Privileged structures — An update , 2000 .
[134] M. Navia,et al. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 , 1989, Nature.
[135] S. O. Smith,et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[136] P. Schiller,et al. Side chain methyl substitution in the delta-opioid receptor antagonist TIPP has an important effect on the activity profile. , 1998, Journal of medicinal chemistry.
[137] K. Garcia,et al. Recognition of angiotensin II: antibodies at different levels of an idiotypic network are superimposable. , 1992, Science.
[138] O. Lichtarge,et al. Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F , 1996, Nature.
[139] M. Schreier,et al. Cyclophilin binds to the region of cyclosporine involved in its immunosuppressive activity , 1987, European journal of immunology.
[140] J M Sturtevant,et al. Heat capacity changes for protein-peptide interactions in the ribonuclease S system. , 1992, Biochemistry.
[141] Amos B. Smith,et al. Novel ligands lacking a positive charge for the δ- and μ-opioid receptors , 2000 .
[142] M. Jaskólski,et al. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. , 1989, Science.
[143] D. Seebach,et al. Novel backbone conformation of cyclosporin A: the complex with lithium chloride , 1992 .
[144] Y. Shigeri,et al. A potent nonpeptide neuropeptide Y Y1 receptor antagonist, a benzodiazepine derivative. , 1998, Life sciences.
[145] C. Martínez-A,et al. HIV-1 infection through the CCR5 receptor is blocked by receptor dimerization. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[146] M. Wolff,et al. BURGER'S MEDICINAL CHEMISTRY AND DRUG DISCOVERY , 1996 .
[147] A. Otaka,et al. An anti-HIV peptide, T22, forms a highly active complex with Zn(II). , 1996, Biochemical and biophysical research communications.
[148] D. Fairlie,et al. Conformational homogeneity in molecular recognition by proteolytic enzymes , 1999, Journal of molecular recognition : JMR.
[149] F A Quiocho,et al. Target enzyme recognition by calmodulin: 2.4 A structure of a calmodulin-peptide complex. , 1992, Science.
[150] E Novellino,et al. Modeling of kappa-opioid receptor/agonists interactions using pharmacophore-based and docking simulations. , 2000, Journal of medicinal chemistry.
[151] C. Hutchison,et al. Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. , 1991, The Journal of biological chemistry.
[152] H. Khorana,et al. Requirement of Rigid-Body Motion of Transmembrane Helices for Light Activation of Rhodopsin , 1996, Science.
[153] J. Chang. Deciphering the structural elements of hirudin C-terminal peptide that bind to the fibrinogen recognition site of alpha-thrombin. , 1991, Biochemistry.
[154] K. Wüthrich,et al. Conformation of recombinant desulfatohirudin in aqueous solution determined by nuclear magnetic resonance. , 1989, Biochemistry.
[155] W. Greenlee,et al. Non-peptide Angiotensin Agonist , 1995, The Journal of Biological Chemistry.
[156] Stephen W. Fesik,et al. A model of the cyclophilin/cyclosporin A (CSA) complex from NMR and X-ray data suggests that CSA binds as a transition-state analog , 1992 .
[157] A. Otaka,et al. Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection. , 1998, Bioorganic & medicinal chemistry.
[158] S. Goodman,et al. Structural and Functional Aspects of RGD-Containing Cyclic Pentapeptides as Highly Potent and Selective Integrin αVβ3 Antagonists , 1996 .
[159] X. P. Liu,et al. The active state of the AT1 angiotensin receptor is generated by angiotensin II induction. , 1996, Biochemistry.
[160] A. Goldman,et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein , 1991, Science.
[161] S. Jurisson,et al. Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[162] G. Rose,et al. Turns in peptides and proteins. , 1985, Advances in protein chemistry.
[163] G. Marshall,et al. Effect of hydroxyl group configuration in hydroxyethylamine dipeptide isosteres on HIV protease inhibition. Evidence for multiple binding modes. , 1991, Journal of medicinal chemistry.
[164] R. Leduc,et al. Photolabeling identifies position 172 of the human AT(1) receptor as a ligand contact point: receptor-bound angiotensin II adopts an extended structure. , 2000, Biochemistry.
[165] E. Purisima,et al. Conformational stability of a thrombin-binding peptide derived from the hirudin C-terminus. , 1992, Biochemistry.
[166] Garland R. Marshall,et al. Conformational Analysis of Reverse-Turn Constraints by N-Methylation and N-Hydroxylation of Amide Bonds in Peptides and Non-Peptide Mimetics , 1998 .
[167] S W Lin,et al. Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[168] R G Smith,et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. , 1998, Science.
[169] M. Ghadiri,et al. Peptide architecture. Design of stable .alpha.-helical metallopeptides via a novel exchange-inert ruthenium(III) complex , 1990 .
[170] G. Wider,et al. Cyclosporin A—cyclophilin complex formation A model based on X‐ray and NMR data , 1992, FEBS letters.
[171] A. Lomize,et al. The transmembrane 7-alpha-bundle of rhodopsin: distance geometry calculations with hydrogen bonding constraints. , 1997, Biophysical journal.
[172] R. Jensen,et al. Reduced peptide bond pseudopeptide analogues of secretin. A new class of secretin receptor antagonists. , 1991, The Journal of biological chemistry.
[173] J. Rizo,et al. Constrained peptides: models of bioactive peptides and protein substructures. , 1992, Annual review of biochemistry.
[174] S. Schreiber,et al. Chemistry and biology of the immunophilins and their immunosuppressive ligands. , 1991, Science.
[175] Garland R. Marshall,et al. A hierarchical approach to peptidomimetic design , 1993 .
[176] R. Leduc,et al. Molecular cloning of a ferret angiotensin II AT(1) receptor reveals the importance of position 163 for Losartan binding. , 2000, Biochimica et biophysica acta.
[177] S. Coughlin,et al. Thrombin signalling and protease-activated receptors , 2000, Nature.
[178] S. Mammi,et al. Conformational studies by circular dichroism, 1H NMR, and computer simulations of bombolitins I and III in aqueous solution containing surfactant micelles. , 1990, Biochemistry.
[179] R. Schwyzer. Peptide–membrane interactions and a new principle in quantitative structure–activity relationships , 1991, Biopolymers.
[180] D. Robertson,et al. Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. , 2000, Journal of medicinal chemistry.
[181] V. Hruby,et al. Conformational and topographical considerations in the design of biologically active peptides , 1993, Biopolymers.
[182] V. Hruby,et al. Conformation-activity relationships of opioid peptides with selective activities at opioid receptors. , 1999, Biopolymers.
[183] W. Bode,et al. Crystal structure of the thrombin‐hirudin complex: a novel mode of serine protease inhibition. , 1990, The EMBO journal.
[184] William L. Neumann,et al. Asymmetric synthesis of highly functionalized polyazamacrocycles via reduction of cyclic peptide precursors , 1994 .
[185] Dudley H. Williams,et al. Aspects of molecular recognition: solvent exclusion and dimerization of the antibiotic ristocetin when bound to a model bacterial cell-wall precursor , 1989 .
[186] K. R. Ely,et al. Synthetic site-directed ligands. , 1989, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[187] M. Saraste,et al. FEBS Lett , 2000 .
[188] M. Hatada,et al. Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. , 1991, Journal of medicinal chemistry.
[189] N. Sewald,et al. Peptides: Chemistry and Biology , 2002 .
[190] J. Zheng,et al. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. , 1991, Science.
[191] W. Vale,et al. Synthetic analogs of the hypothalamic luteinizing hormone releasing factor with increased agonist or antagonist properties. , 1973, Biochemistry.
[192] I. Hamachi,et al. Guest-Induced Umpolung on a Protein Surface: A Strategy for Regulation of Enzymatic Activity , 2000 .
[193] K. Blumer,et al. G-protein-coupled receptors function as oligomers in vivo , 2000, Current Biology.
[194] R. Poljak,et al. Three-dimensional structure of an idiotope–anti-idiotope complex , 1990, Nature.
[195] D. Patel,et al. RNA architecture dictates the conformations of a bound peptide. , 1999, Chemistry & biology.
[196] S. Rees,et al. Chapter 24. Oligomerisation of G protein-coupled receptors , 2000 .
[197] C. Strader,et al. A single amino acid substitution in the beta-adrenergic receptor promotes partial agonist activity from antagonists. , 1989, The Journal of biological chemistry.
[198] F. Young. Biochemistry , 1955, The Indian Medical Gazette.
[199] R. Jensen,et al. Probing peptide backbone function in bombesin. A reduced peptide bond analogue with potent and specific receptor antagonist activity. , 1988, The Journal of biological chemistry.
[200] M. Casu,et al. Cyclic pentapeptides of chiral sequence DLDDL as scaffold for antagonism of G-protein coupled receptors: synthesis, activity and conformational analysis by NMR and molecular dynamics of ITF 1565 a substance P inhibitor. , 1999, Biopolymers.
[201] R. Dixon,et al. Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution. , 1991, The Journal of biological chemistry.
[202] W. Delano,et al. Convergent solutions to binding at a protein-protein interface. , 2000, Science.
[203] B Kohl,et al. From peptide to non-peptide. 3. Atropisomeric GPIIbIIIa antagonists containing the 3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione nucleus. , 1997, Journal of medicinal chemistry.
[204] O. Nishimura,et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[205] J. Rivier,et al. Betidamino acids: versatile and constrained scaffolds for drug discovery. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[206] D. Fairlie,et al. Protease inhibitors: current status and future prospects. , 2000, Journal of medicinal chemistry.
[207] Garland R. Marshall,et al. Constrained Peptidomimetics for TRH: cis-Peptide Bond Analogs , 2000 .